ARTICLE | Company News
Philogen, Bayer deal
February 21, 2011 8:00 AM UTC
Philogen's most advanced compound, Darleukin ( L19-IL2), a fusion protein consisting of the human vascular targeting antibody L19 and IL-2, has completed Phase II testing to treat renal cell carcinom...